Literature DB >> 33031539

Axicabtagene ciloleucel for relapsed or refractory lymphoma after prior treatment with a different CD19-directed CAR T-cell therapy.

Victor A Chow1,2, Ajay K Gopal1,2, Jordan Gauthier1,2, Yolanda D Tseng1,3, Cameron J Turtle1,2, David G Maloney1,2, Mazyar Shadman1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2020        PMID： 33031539      PMCID： PMC7556120          DOI： 10.1182/bloodadvances.2020002292

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  5 in total

1.  Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma.

Authors:  Stephen J Schuster; Michael R Bishop; Constantine S Tam; Edmund K Waller; Peter Borchmann; Joseph P McGuirk; Ulrich Jäger; Samantha Jaglowski; Charalambos Andreadis; Jason R Westin; Isabelle Fleury; Veronika Bachanova; S Ronan Foley; P Joy Ho; Stephan Mielke; John M Magenau; Harald Holte; Serafino Pantano; Lida B Pacaud; Rakesh Awasthi; Jufen Chu; Özlem Anak; Gilles Salles; Richard T Maziarz
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.

Authors:  Cameron J Turtle; Kevin A Hay; Laïla-Aïcha Hanafi; Daniel Li; Sindhu Cherian; Xueyan Chen; Brent Wood; Arletta Lozanski; John C Byrd; Shelly Heimfeld; Stanley R Riddell; David G Maloney
Journal:  J Clin Oncol       Date:  2017-07-17       Impact factor: 44.544

3.  Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma.

Authors:  Sattva S Neelapu; Frederick L Locke; Nancy L Bartlett; Lazaros J Lekakis; David B Miklos; Caron A Jacobson; Ira Braunschweig; Olalekan O Oluwole; Tanya Siddiqi; Yi Lin; John M Timmerman; Patrick J Stiff; Jonathan W Friedberg; Ian W Flinn; Andre Goy; Brian T Hill; Mitchell R Smith; Abhinav Deol; Umar Farooq; Peter McSweeney; Javier Munoz; Irit Avivi; Januario E Castro; Jason R Westin; Julio C Chavez; Armin Ghobadi; Krishna V Komanduri; Ronald Levy; Eric D Jacobsen; Thomas E Witzig; Patrick Reagan; Adrian Bot; John Rossi; Lynn Navale; Yizhou Jiang; Jeff Aycock; Meg Elias; David Chang; Jeff Wiezorek; William Y Go
Journal:  N Engl J Med       Date:  2017-12-10       Impact factor: 91.245

4.  The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells.

Authors:  Alexandre V Hirayama; Jordan Gauthier; Kevin A Hay; Jenna M Voutsinas; Qian Wu; Ted Gooley; Daniel Li; Sindhu Cherian; Xueyan Chen; Barbara S Pender; Reed M Hawkins; Aesha Vakil; Rachel N Steinmetz; Utkarsh H Acharya; Ryan D Cassaday; Aude G Chapuis; Tejaswini M Dhawale; Paul C Hendrie; Hans-Peter Kiem; Ryan C Lynch; Jorge Ramos; Mazyar Shadman; Brian G Till; Stanley R Riddell; David G Maloney; Cameron J Turtle
Journal:  Blood       Date:  2019-02-19       Impact factor: 22.113

5.  Outcomes of patients with large B-cell lymphomas and progressive disease following CD19-specific CAR T-cell therapy.

Authors:  Victor A Chow; Ajay K Gopal; David G Maloney; Cameron J Turtle; Stephen D Smith; Chaitra S Ujjani; Mazyar Shadman; Ryan D Cassaday; Brian G Till; Yolanda D Tseng; Edus H Warren; Andrei R Shustov; Manoj P Menon; Sandra Bhark; Utkarsh H Acharya; Erin Mullane; Lindsay M Hannan; Jenna M Voutsinas; Ted A Gooley; Ryan C Lynch
Journal:  Am J Hematol       Date:  2019-05-21       Impact factor: 10.047
  5 in total
  1 in total

1.  CD19 CAR-T expressing PD-1/CD28 chimeric switch receptor as a salvage therapy for DLBCL patients treated with different CD19-directed CAR T-cell therapies.

Authors:  Yun Liang; Hui Liu; Zheming Lu; Wen Lei; Chaoting Zhang; Ping Li; Aibin Liang; Ken H Young; Wenbin Qian
Journal:  J Hematol Oncol       Date:  2021-02-16       Impact factor: 17.388
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.